CURRICULUM VITAE



CURRICULUM VITAE

NAME: Michael James Naslund, M.D., M.B.A.

TITLE: Professor of Surgery (Urology)

Director, Maryland Prostate Center

Chief, Division of Urology, University of Maryland School of Medicine

ADDRESS:

Office: 29 S. Greene Street, Suite 500 Baltimore, MD 21201

Phone: (410) 328-0800

FAX: (410) 328-2048

EDUCATION:

1973-1977: B.S. (1977) Davidson College

Davidson, North Carolina

1977-1981: M.D. (1981) The Johns Hopkins University

School of Medicine, Baltimore, Maryland

1990-1992: M.B.A. (1992) The Wharton School of Finance,

Philadelphia, Pennsylvania

RESIDENCY TRAINING:

1981-1983 General Surgery Residency

The Johns Hopkins Hospital

Baltimore, Maryland

1983-1987 Urology Residency

The Johns Hopkins Hospital

Baltimore, Maryland

CERTIFICATION:

1990 Diplomate, American Board of Urology

MEDICAL LICENSURE:

1981 Maryland

MAJOR INTERESTS:

Prostate cancer

Benign prostatic hyperplasia

Chronic prostatitis

Healthcare Finance and Management

EMPLOYMENT:

1988 - 1990 Department of Urology

The Johns Hopkins Hospital

Baltimore, Maryland

1990 - PRESENT Division of Urology

University of Maryland School of Medicine

Baltimore, Maryland

1992 - PRESENT Founder and Director

The Maryland Prostate Center

University of Maryland School of Medicine

2006-PRESENT Chief, Division of Urology

University of Maryland School of Medicine

PROFESSIONAL MEMBERSHIPS:

1991 American Medical Association

1991 American Urological Association

1991 Mid-Atlantic Section - American Urological Assoc.

1992 American Association of Clinical Urologists

MAJOR CONSULTANTSHIPS:

1993 – 1999 American Urological Association: Healthcare Policy Committee

1993 – 1999 Mid-Atlantic Section, American Urological Association: Socioeconomics Committee Chairman

1993 - PRESENT Board Member, American Prostate Society

Baltimore, Maryland

1993 – 1997 American Cancer Society: Cancer Care Committee

1993 Maryland Department of Health and Mental Hygiene: Cancer Detection Task Force

1995 – 1997 Chairman, Prostate Cancer Detection Committee for Maryland, American Cancer Society

1996 – 2002 Board Member, American Association of Clinical Urologists

1999 – 2007 American Urological Association: Investment Committee

2003. President, American Assoc. of Clinical Urologists

2007-2008 President, Mid-Atlantic Section, American Urological Association

GRANT SUPPORT:

11/1/92 to 11/1/94 Naslund, M.J., P. I.: A Clinical Trial Comparing the Safety and Efficacy of Alpha Blockade and Androgen Suppression for the Treatment of Benign Prostatic Hyperplasia. Veterans Administration Cooperative Study #359. Total amount of award $160,000.

3/3/93 to 3/3/94 Naslund, M.J., P. I.: Prostate Disease Detection. Maryland Department of Health and Mental Hygiene. Total amount of award $75,000.

5/1/95 to 5/1/97 Naslund, M.J., P. I.: A Multicenter Clinical Investigation of Transurethral Needle Ablation (TUNA) in Patients with Benign Prostatic Hyperplasia. VIDAMED CORP. Total amount of award $270,000.

6/95 to 6/02 Jacobs, S.C. and Naslund, M.J., Co-P. I.: Medical Therapy in Benign Prostatic Hyperplasia. NIH #1UOIDK49880-01. Total amount of award $1,876,000.

5/01 to 5/02 Naslund, M.J., PI: A Randomized Study with Microwave Uroplasty and Proscar For The Treatment of Benign Prostatic Hyperplasia. Celsion Corp. Total amount of award $9,000.

11/01 to 6/04 Naslund, M.J., PI: Long-Term Efficacy and Safety of Alfuzosin On The Risk Of Acute Urinary Retention and the Need For Surgery in Patient with Benign Prostatic Hyperplasia. A Two-Year Randomized Multi-Center Double Blind Parallel Group Placebo-Controlled Study. Sanofi-Synthelabo Corp. Total amount of award $140,000.

9/02 to 6/11 Naslund, M.J., PI: Alternative Therapies for Benign Prostatic Symptoms. NIH# 1U01 DK63778-01. Total amount of award $2,050,000.

7/10 to 6/14 Holt, C, PI: Prostate Cancer Education in African American Churches. Sub-Award Q254003 Naslund, M.J. Total amount of sub-award $92,056

PUBLICATIONS:

1. Naslund, M.J., Pearson, T.A. and Ritter, J.A.: A documented episode of pulmonary vasoconstriction and systemic sclerosis. Johns Hopkins Medical Journal, 148:(2) 78,1981.

2. Naslund, M.J. and Coffey, D.S.: The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. Journal of Urology, 136: 1136, 1986.

3. Naslund, M.J. and Coffey, D.S.: The hormonal imprinting of the prostate and the regulation of stem cells in prostatic growth. Benign Prostatic Hyperplasia, Volume 2, p. 73, 1987. NIH Publication No. 87-2887, U.S. Govt. Printing Office, Washington, D.C.

4. Naslund, M.J., Strandberg, J.D. and Coffey, D.S.: The role of androgens and estrogens in the pathogenesis of experimental non-bacterial prostatitis. Journal of Urology, 140:1049, 1988.

5. Naslund, M.J., Gearhart, J.P. and Jeffs, R.D.: Laparoscopy: Its selected use in patients with unilateral non-palpable testis after HCG stimulation. Journal of Urology, 142:108, 1989.

6. Jacobs, S.C., Campbell, Jr., E.W. and Naslund, M.J.: Current Status of Cancers of the Bladder and Prostate. Transactions of ALIMDA, 74:144, 1990.

7. Hildebrand, R.K., Naslund, M.J., Oesterling, J.E. and Coffey, D.S.: The influence of age, strain and the testes on rat hormone sensitivity. Prostate, 18:81, 1991.

8. Naslund, M.J.: Vesical fistulae. In: Operative Urology, Edited by F. F. Marshall, Philadelphia: W. B. Saunders, Co. Chapt. 22, pp 151-156, 1991.

9. Naslund, M.J.: Vasectomy. In: Operative Urology, Edited by F. F. Marshall, Philadelphia: W. B. Saunders, Co. Chapt. 52, pp. 397-398, 1991.

10. Naslund, M.J., Dement, S. and Marshall, F.F.: Malignant renal schwannoma. Urology, 38:(5) 477-479, 1991.

11. Quinlan, D.M., Brendler, C.B. and Naslund, M.J.: Urological Applications of the Argon Beam Coagulator. Journal of Urology, 147:410, 1992.

12. Naslund, M.J., Campbell, E.W., Jr., Jacobs, S.C.: Laparoscopic Pelvic Lymph Node Dissection. Journal of Urological Nursing, 11:20, 1992.

13. Steiner, M.S., Naslund, M.J., Stutzman, R.E.: Modified Thoraco-Abdominal Approach for Retroperitoneal Lymphadenectomy. Journal of Urology, 149:23, 1993.

14. Thompson, R.A., Campbell, E.W. Jr., Kramer, H.C., Jacobs, S.C., and Naslund, M.J.; Late Invasive Recurrence Despite Long-Term Surveillance for Superficial Bladder Cancer. Journal of Urology 149: 1010, 1993

15. Choe, J.W., Campbell, E.W., Jr., Naslund, M.J., Jacobs, S.C.: Management of Renal Carcinoma. In: Practice of Urology (eds Smith, J., Stein, B. ) New York: Norton Medical Books, 1993, Vol 2 pp. 1-23.

16. Hader, J.E., Marzella, L. Myers, R.A.M., Jacobs, S.C., Naslund, M.J.: Hyperbaric Oxygen Treatment for Experimental Cyclophosphamide induced Hemorrhagic Cystitis. Journal of Urology 149; 1617, 1993.

17. Burney, T.L., Campbell, E.W., Jr., Naslund, M.J., Jacobs, S.C.: Complications of Staging Laparoscopic Pelvic Lymphadenectomy. Surgical Laparoscopy Endo 3: 184-190, 1993.

18. Burney, T.L., Jacobs, S.C., Naslund, M.J.: Small bowel obstruction following laparoscopic lymph adenectomy, Journal of Urology 150: 1515, 1993.

19. Naslund, M.J., Sklar, G.N., and Jacobs, S.C.: The Prostate: Why Does It Enlarge? What Should I Do About It. The American Prostate Society Update Network. Producer Shirley Gerard. The Aherne Group/Monumental Films, 1994.

20. Naslund, M.J.: The Economics of Health Care Reform. Urology 44: 299, 1994

21. Benoit, R.M., and Naslund, M.J.: An Economic Rationale for Prostate Cancer Screening. Urology 44: 795, 1994

22. Naslund, M.J.: Cost Considerations in the Treatment of BPH. American Journal of Medicine Suppl. Current Management of Benign Prostatic Hyperplasia: Nov. 23, 1994.

23. Naslund, M.J., Campbell, E.W., Jr., Jacobs, S.C.: Pelvic Lymphadenectomy. In: Complications of Laparoscopic Surgery (ed. Robert W. Bailey, M.D.) St. Louis: Quality Medical Publishing, Inc.; Ch. 14 pp 341-361, 1995.

24. Campbell, E.W., Jr., Jacobs, S.C., Naslund, M.J.: Complications of Laparoscopic Urologic Surgery: Miscellaneous Urologic Procedures in: Complications of Laparoscopic Surgery ed. R. W. Bailey and J. L. Flowers: St. Louis: Quality Medical Publishing, Inc.; Ch. 13, pp 329-340, 1995.

25. Benoit, R.M. and Naslund, M.J.: Detection of Latent Prostate Cancer from Routine Screening: Comparison with Breast Cancer Screening. Urology 46: 533, 1995.

26. Sklar, G.N., Koskorove, G., Filderman, P.S., Naslund, M.J. and Jacobs, S.C.: Laparoscopic Monitoring of Cryosurgical Ablation of the Prostate. Surgical Laparoscopy & Endoscopy 5 (5): 376-81, 1995.

27. Naslund, M.J. and Stitcher, M.F.: A Cost Comparison of TUNA vs. TURP. Journal of Urology 157: 155A, 1997.

28. Mackey, T.J., Flowers, J.L., Bartlett, S.T., Cho, E., Jacobs, S.C. and Naslund, M.J.: Cost Comparison of Laparoscopic vs. Open Donor Nephrectomy Analyzing Provider Charges and Productivity Loss. Journal of Urology 157: 156A, 1997.

29. Benoit, R.M. and Naslund, M.J.: Socioeconomic Effects of Prostate Cancer Screening. Urologic Clinics of North America 24(2): 451, 1997.

30. Naslund, M.J.: Transurethral Needle Ablation of the Prostate.

Urology 50 167, 1997.

31. Benoit, R.M. and Naslund, M.J.: The Economics of Prostate Cancer Screening. Oncology 11: 1533, 1997.

32. Benoit, R.M. and Naslund, M.J.: The Economics of Prostate Cancer Screening.

Primary Care and Cancer 17:9, 1997.

33. Roehrbron, C.G., Issa, M.M., Bruskewitz, R.C., Naslund, M.J., Oesterling, J.E., Perez-Marrero, R., Shumaker, B.P. and Narayan, P.: Transurethral Needle Ablation for Benign Prostatic Hyperplasia: Twelve Month Results of a Prospective Multicenter U.S. Study. Urology, 51: 415, 1998.

34. Bruskewitz, R.C., Issa, M.M., Roehrbron, C.G., Naslund, M.J., Perez-Marrero, R., Shumaker, B.P. and Oesterling, J.E.: A Prospective, Randomized One Year Clinical Trial Comparing Transurethral Needle Ablation to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia. Journal of Urology, 159: 1588, 1998.

35. Gee, W.H., Holtgrewe, H.L., Blute, M.L., Miles, B.J., Naslund, M.J., Nellans, R.E., O’Leary, M.P., Thomas, R., Painter, M.R., Meyer, J.J., Rohner, T.J., Cooper, T.P., Blizzard, R., Fenninger, R.B., and Emmons, L.: 1997 American Urological Association Galant Survey: Changes in Diagnosis and Management of Prostate Cancer and Benign Prostatic Hyperplasia, and Other Practice Trends From 1994 to 1997. Journal of Urology, 160: 1804, 1998.

36. Sperry, R.J., Naslund, M.J., and Baum, N.: The Principles of Economic Analysis. Costs and Quality: 5, 7-11, 1999.

37. Roehrborn, C.J., Burkhard, F.C., Bruskewitz, R.C., Issa, M.M., Perez-Marrero, R., Naslund, M.J., and Shumaker, B.P.: The Effects of Transurethral Needle Ablation and Resection of the Prostate on Pressure Flow Urodynamic Parameters: Analysis of the United States Randomized Study. Journal of Urology, 162: 92, 1999.

38. O’Leary, M.P., Gee, W.F., Holtgrewe, H.L., Blute, M.L., Cooper, T.P. Meyer, J.J., Miles, B.J., Naslund, M.J., Nellans, R.E., Thomas, R., Painter, M.R., Blizzard, R., and Fenninger, R.B.: 1998 American Urological Association Gallup Survey: Changes in Physician Practice Patterns, Treatment of Ureteral Stones and Impact of Managed Care. Journal of Urology, 162: 1702, 1999.

39. Mathews, R., Naslund, M., and Docimo, S.: Cost Analysis of the Treatment of Vesicoureteral Reflux: A Computer Model. Journal of Urology, 163: 561, 2000.

40. Benoit, R.M., Naslund, M.J., and Cohen, J.K.: Complications After Prostate Brachytherapy In the Medicare Population. Urology, 55: 91, 2000.

41. Chon, J.K., Jacobs, S.C., and Naslund, M.: The Cost Value of Medical Versus Surgical Hormonal Therapy for Metatastatic Prostate Cancer. Journal of Urology, 164: 735, 2000.

42. Naslund, M., Bay-Nielsen, H., Holtgrewe, L., Homma, Y., and Melchior, H.: The Economics of Benign Prostatic Hyperplasia. In: Benign Prostatic Hyperplasia, Ed. by Chatelain, C., Denis, L., Foo, K., Khoury, S., and McConnell, J., Plymouth, U.K.: Health Publications Ltd. Chapter 2 pp. 69-78, 2001.

43. Benoit, R.M., Gronberg, H., and Naslund, M.J.: A Quantitative Analysis of the Costs and Benefits of Prostate Cancer Screening. Prostate Cancer and Prostatic Diseases 4: 138-145, 2001.

44. Dibiase, S.J., Hosseinzadeh, K., Gullapalli, R.P., Jacobs, S.C., Naslund, M.J., Sklar, G.N., Alexander, R.B. and Yu, C.: Magnetic Resonance Spectroscopic Imaging-Guided Brachytherapy For Localized Prostate Cancer. Int. J. Radiation Oncology Biol. Phys. 52: 429, 2002.

45. Kwok, Y., DiBiase, SJ, Amin, P., Naslund, M., Sklar, G, and Jacobs, S.C.: Risk Group Stratification In Patients Undergoing Permanent I 125 Prostate Brachytherapy As Monotherapy. Int. J. Radiation Oncology Biol. Phys., Vol. 53, No.3, pp. 558, 2002.

46. Benoit, R.M., Wise, B.V., Naslund, M.J., Mathews, R., and Docimo, S.G.: The Effect of Dysfunctional Voiding On The Costs of Treating Vesicoureteral Reflux: A Computer Model. Journal Of Urology, 168: 2173, 2002.

47. Hill, B., Belville, W., Bruskewitz, R., Issa, M., Perez-Marrero, R., Roehrborn, C., Terris, M. and Naslund, M. Transurethral Needle Ablation vs. Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia: 5-Year Results of a Prospective Randomized Multi-Center Clinical Trial. Journal of Urology 171: 2336, 2004.

48. Naslund, M.J.: What Is The Role of Combination Medical Therapy In Treating Prostatic Symptoms? Pri-Med In Practice. 3: 2, 2005.

49. Naslund, M.J., Carlson, A.M., and Williams, M.J.: A Cost Comparison of Medical Management and Transurethral Needle Ablation for Treatment of Benign Prostatic Hyperplasia During a 5-Year Period. Journal of Urology, 173: 2090, 2005.

50. Naslund, M.J.: Medical and Surgical Treatments to Relieve Symptoms of Benign Prostatic Hyperplasia. American Prostate Society Quarterly News, Spring 2006.

51. Naslund, M., Chiao, E., Black, L., and Eaddy, M.: The Hidden Condition: Status, Chalenges, and Opportunities in the Management of Enlarged Prostate for Managed Care. The Am. J. of Managed Care 12: No. 4, “Suppl.” 76, 2006.

52. Fenter, T.C., Naslund, M.J., Shah, M.B., Eaddy, M.T. and Black, L.: The Cost of Treating the 10 Most Prevalent Diseases in Men 50 Years of Age or Older. The Am. J. of Managed Care 12: No. 4, “Suppl.” 90, 2006.

53. Black, L., Naslund, M.J., Gilbert, T.D., Davis, A. and Ollendorf, D.A. An Examination of Treatment Patterns and Cost of Care Among Patients With Benign Prostatic Hyperplasia. The Am. J. of Managed Care 12: No.4, “Suppl.” 99, 2006.

54. Naslund, M., Issa, M., Grogg, A., Eaddy, M., and Black, L.: Clinical and Economical Outcomes in Patients Treated for Enlarged Prostate. The Am. J. of Managed Care 12: No.4, “Suppl.” 111, 2006.

55. Kaplan, S., Naslund, M.: Public, Patient and Professional Attitudes Toward the Diagnosis and Treatment of Enlarged Prostate: A Landmark National US Survey. Int. J. Clin. Pract. 10: 1157, 2006.

56. Naslund, M.J., Costa, F.J., and Miner, M.M.: Managing Enlarged Prostate in Primary Care. Int. J. Clin. Pract. 60: 1609, 2006.

57. Naslund, M.J. and Miner, M.: A Review of the Clinical Efficacy and Safety of 5-Alpha Reductase Inhibitors for the Enlarged Prostate. Clinical Therapeutics 29: 17, 2007.

58. Naslund, M., Black, L., Eaddy, M. and Batiste, L.: Finasteride vs Dutasteride: A Real World Economic Evaluation. The Am. J. of Managed Care. 13: S17, 2007.

59. Naslund, M.J., Gilsenan, A.W., K Midkiff, A. Brown, E.T. Wolford and J. Wang: Prevalence of Lower Urinary Tract Symptoms and Prostate Enlargement in the Primary Care Setting. Int. J. of Clinical Practice. 61:1437, 2007.

60. Naslund, M., Regan, T., Ong, C. and Hogue, S.:5-Alpha-Reductase Inhibitors In Men With An Enlarged Prostate: An Evaluation of Outcomes and Therapeutic Alternatives. The Am. J. of Managed Care. 14: S148, 2008.

61. Naslund, M., Eaddy, M., Kruep, E. And Hogue, S.: Cost Comparison of Finasteride and Dutasteride For Enlarged Prostate in a Managed Care Setting Among Medicare-aged Men . The Am. J. of Mangaed Care. 14: S167, 2008.

62. Naslund, M., Eaddy, M., Hogue, S. and Kruep, E.:Impact of Delaying 5-Alpha-Reductase Inhibitor Therapy in Men on Alpha-Blocker Therapy to Treat BPH: Assessment of Acute Urinary Retention and Prostate-Related Surgery. Current Medical Research and Opinion 25:2663, 2009.

63. Sausville, J. and Naslund, M.: Benign Prostatic Hyperplasia and Prostate Cancer: An Overview For Primary Care Physicians. Int. J. Of Clinical Practice. 64: 1740, 2010.

64. Naslund, M.J., Eaddy, M.T., Hogue, S.L., Kruepp, E. J., and Shah, M.B.: The Economic Impact of Delaying 5-Alpha Reductase Inhibitor Therapy in Men Receiving Treatment for Symptomatic Benign Prostatic Hyperplasia. Am. Health Drug Benefits 4:155, 2011.

65. Helfand, B..T., McVary, K. T., Meleth, S., Sharp, V., Foster, H., Naslund, M. J. and Williams, O.D.: The Relationship Between Lower Urinary Severity and Sleep Disturbance in the CAMUS Trial. Journal of Urology 185: 2223, 2011.

66. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE Jr, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT; Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group. JAMA. 2011 Sep 28;306(12):1344-51.

67 Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH, Stephens RM, Croce CM, Ambs S. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 2011; 40:3689

68 Helfand, BT, , Lee JY, McVary KT; Naslund MJ, Sharp, V. Williams OD, Harris,F. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology 2012;188(6):2288-93.

69. Saunders DR, Holt CL, Whitehead T,  Atkinson N, Le D, Wang MQ, Slade J, Muwwakkil B, Williams R, Schulz E, Naslund M.     Development of the Men’s Prostate Awareness Church Training (M-PACT):  Church-based Workshops for African American Men.  Family & Community Health 2013;36(3):224-235.

70. Holt, CL,Saunders, DR, Wang, MQ, Slade, JL, Muwwakkil, B, Williams, R, Atkinson, NL, Whitehead, TL and Naslund, MJ. Informed Decision-Making and Satisfaction with a Church-Based Men’s Health Workshop Series for African-American Men:Men-Only vs. Mixed Gender Format. J. Cancer Educ. 2015: 30(3), 530-534.

71. [pic][pic]See comment in PubMed Commons belowSaunders, D.R., Holt, C.L., Le, D., Slade, J.L., Muwwakkil, B., Savoy, A., Williams, R., Whitehead, T.L., Wang, MQ, Naslund, M., (2015). Recruitment and Participation of African American Men in Church-based Health Promotion Workshops. Journal of Community Health 2015, :40 (3) June 19.

72. Costello, L.C., Franklin, R.B., Zou, J. and Naslund, M.J.: Evidence that Human Prostate Cancer is a ZIP-1- Deficient Malignancy that could be Effectively Treated with a Zinc Ionophore(Clioquinol) Approach. Chemotherapy 2015; 4(2): 1-10.

73. Robyn L. Prueitt1,12, Tiffany A. Wallace1,12, Sharon A. Glynn1,12*, Ming Yi2, Wei Tang1, Jun Luo3, Tiffany H. Dorsey1, Katherine E. Stagliano4, John W. Gillespie5, Robert S. Hudson1, Atsushi Terunuma1, Jennifer L. Shoe6, Diana C. Haines7, Harris G. Yfantis8, Misop Han3, Damali N. Martin1, Symone V. Jordan1, James F. Borin9, Michael J. Naslund9, Richard B. Alexander9, Robert M. Stephens2, Christopher A. Loffredo10, Dong H. Lee8, Nagireddy Putluri11, Arun Sreekumar11, Arthur A. Hurwitz5, and Stefan Ambs1:: An immune-inflammation gene expression signature in prostate tumors of smokers. IN PRESS Cancer Research 2016

74. Franklin, R., Zou, J., Zheng, Y., Naslund, M., and Costello, L.:Zinc Ionophore (Clioquinol) Inhibition of Human ZIP1-Deficient Prostate Tumor Growth in the Mouse Xenograft Model: A Zinc Approach for the Efficacious Treatment of Prostate Cancer. Intl. Journal of Cancer and Clinical Research 2016, 3:037

75. Onukwugha, E., Yong, C., Naslund, M., Woods, C., Mullins, D., Seal, B. and Hussain, A.: Specialist visits and initiation of cancer-directed treatment among a large cohort of men diagnosed with prostate cancer. Urologic Oncology 35(2017) 150.e17-150.e23.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download